Key Proteo develops first newborn testing kit prototype

Key Proteo achieved a significant milestone this month, developing its first prototype of the newborn testing kits. The proprietary technology will make it possible to screen 4 new target conditions (i.e., Wilson disease, WAS, XLA, and ADA deficiency) in newborns for the very first time.

Validation of the kits began in September and once completed, Key Proteo will pilot a large-scale study with the Washington State on 50~70k newborns. This is projected to start in November, 2021.